Last updated: July 18, 2026
Collegium Pharma v. Teva (1:18-cv-00300): Litigation Summary, Patent Theories, and Generic Risk Outlook
Executive summary: Collegium Pharmaceutical, Inc. v. Teva Pharmaceuticals USA, Inc. (1:18-cv-00300) is a U.S. patent infringement case arising from Teva’s FDA regulatory submission for a Collegium opioid product and the associated Orange Book-listed patent estate. The matter targets specific, listed patents tied to the branded drug’s protected aspects and is litigated in the framework of Hatch-Waxman patent enforcement via infringement and invalidity contentions. The litigation’s practical impact is to delay or deter generic entry while preserving the branded product’s exclusivity-relevant patent barriers, and it affects follow-on risk across formulation, method-of-use, and manufacturing-related claims that could be asserted against future applicants.
What patents are asserted in Collegium Pharmaceutical, Inc. v. Teva Pharmaceuticals USA, Inc. (1:18-cv-00300)?
Answer: The case is organized around Hatch-Waxman enforcement of specific Orange Book patents tied to Teva’s ANDA for a Collegium-branded opioid product. The operative patents and claim groupings are pleaded in the infringement complaint and mirrored in Teva’s invalidity and non-infringement responses.
Patent-assertion pattern in Hatch-Waxman opioid cases
Collegium’s opioid portfolio has historically involved protected features such as:
- Extended-release or abuse-deterrent formulation architecture (composition and formulation claims)
- Manufacturing methods (process claims)
- Drug-device or drug-product structure constraints (where claimed)
- Use-based claims (method-of-use for dosing regimens, patient populations, or therapeutic objectives)
In the Hatch-Waxman posture, the court’s infringement analysis is claim-specific and typically focuses on whether the generic’s ANDA-described formulation or use instructions fall within the asserted claims.
What to extract from the docket
For business decisions, the key items are:
- The asserted patent numbers (one or more)
- The independent claim set asserted (claim categories)
- Whether the case includes willful infringement allegations
- Whether the pleadings include “failure to provide adequate notice” or ANDA carve-outs
- Whether the asserted patents include formulation, method-of-use, and/or manufacturing claim families
(Those particulars are contained in the complaint and the operative scheduling order entries for this docket.)
What are the core legal claims and defenses in 1:18-cv-00300?
Answer: The dispute follows standard Hatch-Waxman litigation structure: Collegium asserts patent infringement; Teva contests with invalidity and non-infringement theories and may attack procedural adequacy.
Collegium’s infringement theories
In these cases, the plaintiff typically:
- Compares the ANDA product as described in the application to each asserted claim limitation
- Argues the generic product’s formulation/process/use meets every limitation of at least one asserted claim
- Uses claim-construction briefing to narrow Teva’s proposed readings
Teva’s defenses
Teva typically raises:
- Non-infringement: the ANDA-described product does not meet one or more claim limitations
- Invalidity under 35 U.S.C. §102 and/or §103 (anticipation/obviousness) and potentially §112 (written description/enablement)
- Non-statutory subject matter theories are less common in this fact pattern category but can appear depending on the asserted claim type
- Prosecution history estoppel or claim-scope arguments to avoid infringement
Claim construction as the pivot
The most business-relevant inflection points are:
- The court’s construction of key limitations
- Any narrowing interpretations that reduce the probability that Teva’s described formulation falls within the asserted scope
When does Collegium v. Teva (1:18-cv-00300) affect FDA exclusivity and generic launch timelines?
Answer: The case affects Teva’s and any other generic entrant’s timing through the combination of (i) patent injunction risk and (ii) the practical settlement or non-settlement posture that determines whether Teva can launch at risk.
How the docket maps to launch risk
- If the court enters a decision upholding infringement (or keeps the asserted patents valid), Teva’s launch can be blocked until expiration.
- If the court invalidates key claims or finds non-infringement, launch could proceed once other regulatory conditions are satisfied.
- If the parties settle, market entry is governed by the settlement effective date and carve-out design (e.g., authorized launch dates, product modifications, and future patent carve-outs).
Exclusivity drivers beyond infringement
Even if litigation favors a generic, the practical ability to launch also depends on:
- Orange Book patent expiration dates
- Whether any additional patents remain listed and un-litigated
- Orphan exclusivity or other exclusivity types, if applicable to the specific product
- Any FDA-related timing constraints (e.g., manufacturing site approval and labeling negotiations)
Is this case a Paragraph IV challenge under Hatch-Waxman?
Answer: The docket posture is consistent with Hatch-Waxman patent enforcement tied to an ANDA submission, which commonly corresponds to a Paragraph IV notice.
What “Paragraph IV” means in litigation terms
In a typical Paragraph IV framework:
- Teva files an ANDA with certifications versus Orange Book patents.
- Collegium receives Paragraph IV notice and sues within statutory timing.
- The automatic stay attaches, delaying FDA approval to launch until resolution or settlement.
Business consequence: If the automatic stay applies, it limits the earliest possible generic market entry absent settlement or court outcomes.
What is the Orange Book status of the challenged patents in 1:18-cv-00300?
Answer: Orange Book-listed patents tied to the branded Collegium opioid product form the asserted patent estate. The court litigation concerns those listed patents’ validity and infringement as to Teva’s ANDA.
How Orange Book drives litigation strategy
Orange Book listings determine:
- Which patents are enforceable in the ANDA dispute
- The automatic stay triggering logic
- Which claims are commercially relevant for the generic launch
For decision-making, the operative list in the case should be cross-walked to:
- Patent expiration dates
- Any “method of use” patents that can be designed around via labeling
- Any formulation patents that can drive design-around needs
How strong is the Collegium patent estate in this litigation?
Answer: Strength is determined by the asserted claim constructions, the validity arguments’ merits, and the likelihood that the generic’s product design maps to the claimed limitations.
Key strength indicators typically used by courts
In opioid formulation and method-of-use patent disputes, strength often turns on:
- Whether asserted claims are supported by credible written description and enablement in the specification
- Whether prior art combinations are properly established for obviousness
- Whether claim construction narrows terms so that the generic product necessarily infringes
Business-reading of strength
- A plaintiff win on infringement after favorable construction implies a high probability of blocking generic entry and can support higher licensing leverage.
- A plaintiff win only on some claims can still preserve partial barriers but may reduce launch restrictions if remaining claims expire earlier.
What generic entry risks exist for Teva and other applicants after 1:18-cv-00300?
Answer: The generic entry risk profile depends on whether the asserted patents survive and whether any design-around path exists that avoids claim limitations without impairing FDA approval.
Risk pathways
- Infringement upheld: Teva’s launch faces injunction risk unless a settlement permits entry.
- Claims invalidated: generic entry can accelerate, and the patent moat compresses.
- Non-infringement: Teva’s launch could proceed if the court’s non-infringement reading aligns with the ANDA product description.
- Partial outcome: only some patents become barriers, shifting risk to the remaining patent set or to future litigation by other patent holders.
Downstream implication
Even if Teva resolves its case, other applicants may still face:
- Same-specification generic products that inherit similar infringement risks
- Related patents not asserted in this case but listed later or held by different assignees
What settlement outcomes typically happen in cases like 1:18-cv-00300 and what do they mean?
Answer: If this case settled, the commercial effect usually is:
- An agreed launch date (or date range) tied to patent expirations
- Product design carve-outs allowing entry only for modified products
- Payments and/or covenant-not-to-sue arrangements
- Allocation of future disputes to specific patents or product versions
Settlement clauses that matter for market entry
- Authorized launch window: earliest date Teva can sell the product
- Labeling commitments: what Teva can or cannot claim in prescribing information
- Stipulated infringement dismissal: scope of release and whether other patents remain enforceable
- Reversion provisions: conditions under which payments cease if FDA or regulatory requirements change
How does Collegium Pharmaceutical’s product compare to Teva’s ANDA product at issue in 1:18-cv-00300?
Answer: The litigation compares the branded opioid formulation and claimed features to Teva’s ANDA-described product.
Where disputes concentrate
For extended-release opioid formulations, court disputes typically concentrate on:
- Drug-release profile and formulation elements
- Abuse-deterrence performance characteristics if claimed
- Manufacturing process controls tied to the asserted method/process claims
- Labeling instructions for method-of-use claims
What happens if the court rules for Teva: does FDA launch proceed immediately?
Answer: A court finding invalidity or non-infringement can remove the patent barrier; however, launch timing still depends on:
- Completion of FDA approval steps and operational readiness
- Whether any remaining Orange Book patents are still enforceable and not stayed
- Any appeal and supersedeas bond or stay pending appeal
What happens if the court rules for Collegium: can Teva still launch “at risk”?
Answer: If the court upholds infringement and validity of the asserted patents, Teva generally faces injunction and cannot safely launch without violating the patent judgment or risking damages and contempt.
Appeal posture
Even with an appeal, courts can maintain injunction coverage unless modified. The appeal’s timing and whether relief is stayed are decisive.
Key Takeaways
- The docket 1:18-cv-00300 is a Hatch-Waxman-style patent dispute tied to Orange Book-listed patents associated with a Collegium opioid product and Teva’s ANDA pathway.
- The litigation’s business impact is launch timing through automatic stay and the probability of injunction depending on claim construction, infringement mapping, and validity outcomes.
- The highest-value analysis for strategy is the list of asserted patents and their claim families, then mapping Teva’s ANDA product description to each asserted limitation.
- Generic entry risk post-case tracks directly to whether the asserted patents survive intact, get narrowed, or get invalidated.
FAQs
- How does an ANDA Paragraph IV notice trigger an automatic stay and how is it reflected in district court timelines for 1:18-cv-00300?
- Which claim construction issues in opioid formulation cases most often determine infringement outcomes between branded and ANDA products?
- How do method-of-use patents affect generic launch risk through labeling carve-outs in Hatch-Waxman litigation?
- What settlement terms most commonly control the earliest generic market entry date after patent litigation with Collegium?
- How should investors evaluate whether a partial win (some claims invalidated) still preserves meaningful exclusivity barriers for the branded product?
References (APA)
- Collegium Pharmaceutical, Inc. v. Teva Pharmaceuticals USA, Inc., No. 1:18-cv-00300 (D. Del. or other district per docket), litigation docket and filings (complaint, responses, claim construction orders, dispositive orders, and judgments).
